Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Cefadroxil

Generic name
Cefadroxil
Brand name
ATC Code
J01DB05

Pharmacokinetics in children

After a single dose of 25 mg/kg, the following parameters were determined in children (n= 20):

  Infants 1 months-1 year (n=8) Infants 1 -2 years (n=12)
Tmax (h) 1 - 2 1 - 2
Cmax (µg/mL) 24,6 ± 5,0 20,4 ± 4,5
T1/2 (h) 2,3 1,8

[SmPC Grüncef®]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Streptococcal pharyngitis
  • Oral
    • 1 month up to 18 years and < 40 kg
      • 25 mg/kg/day in 1 dose
    • 1 month up to 18 years and ≥ 40 kg
      • 1.000 mg/day in 1 dose
    • 1 month up to 18 years and < 40 kg
      [1] [2]
      • 25 mg/kg/day in 1 dose
    • 1 month up to 18 years and ≥ 40 kg
      [1] [2]
      • 1.000 mg/day in 1 dose

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

all indications except tonsillitis:

GFR >50 ml/min/1.73 m2: no dose adjustment needed
GFR 25-50 ml/min/1.73 m2: start at 100% of regular single dose, continue with 50% of regular daily dose in 2 single doses, dosing interval 12 hours
GFR 10-25 ml/min/1.73 m2: start at 100% of regular single dose, continue with 25% of regular daily dose once daily (dosing interval 24 hours)
GFR <10 ml/min/1.73 m2: start at 100 % of regular single dose, continue with 25% of regular daily dose once every 36 hours (dosing interval 36 hours

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. INFECTOPHARM Arzneimittel und Consilium GmbH, SmPC GRÜNCEF® 500 mg/5 mL Trockensaft, Pulver zur Herstellung einer Suspension zum Einnehmen (2532.01.02), 09/2020
  2. INFECTOPHARM Arzneimittel und Consilium GmbH, SmPC GRÜNCEF® 1g Tabletten (179.00.02), 11/2018
  3. Peltola H,, Acute osteomyelitis in children, N Engl J Med, 2014, Jan 23;370(4), 352-60
  4. Lorrot M et al., Antibiotic therapy of bone and joint infections in children: proposals of the French Pediatric Infectious Disease Group., Arch Pediatr., 2017, S36-S41, DOI: 10.1016/S0929-693X(17)30517-1
  5. Peltola H et al., Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial, Clin Microbiol Infect, 2012, 18(6):582-589, DOI: 10.1111/j.1469-0691.2011.03643.x

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes